THE US Food and Drug Administration has approved Rydapt (midostaurin) from Novartis for the treatment of adults with newly diagnosed acute myeloid leukaemia (AML) with a specific genetic mutation called FLT3.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 May 17